Burden and Etiopathogenesis of Chronic Hand Eczema: A Complex Interplay of Genes, Environment, and Exposures
Authors: Molin, S., Yeung, J., & Bissonnette, R Different morphological and etiological subtypes of CHE appear to have overlapping and distinct features related to gene expression, proteomics, inflammatory biomarkers, and metagenomics, but data are limited and derived from small patient cohorts. The available evidence points to the broad activation of immune pathways implicated in JAK-STAT […]
The Gut Microbiome of Non-Atopic Chronic Hand Eczema (CHE) Subjects is Distinct and Enriched in Immuno-Modulatory Bacteria Species compared to Atopic-CHE and Healthy Subjects
Authors: Bissonnette R, Salem Y, Palijan A, Maari C, Proulx ES, Prifti DK, Hunter S, Routy B,Elkrief A. Read more on pubmed
Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials
Authors: Bissonnette R, Albreiki F, Ehst BD, Al Hammadi A, Schliemann S, Yang B, Zhang J, BunickCG. Read more on pubmed
Correction to: Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double‑Blind, Phase 3 Trials
Authors: Bissonnette R, Albreiki F, Ehst BD, Hammadi AA, Schliemann S, Yang B, Zhang J, Bunick CG Read more on pubmed
Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema.
Authors:Thaçi D, Gooderham M, Lovato P, Madsen DE, Soehoel A, Bissonnette R. Read more on pubmed
Reflections on chronic hand eczema – Authors’ reply.
Authors: Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, Crépy MN, Stingeni L, Serra-Baldrich E, Baranowski K, Korn S, Kurvits M, Plohberger U, Strange Vest N, Schliemann S. Read more on pubmed
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials
Authors: Gooderham M, Molin S, Bissonnette R, Worm M, Crépy MN, Stingeni L, Warren RB, Schliemann S, Schuttelaar ML, Ferrucci S, Serra-Baldrich E, Silverberg JI, Balita-Crisostomo CL, Oesterdal ML, Plohberger U, Agner T. Read more on pubmed
Hand Eczema. Part 1: epidemiology, pathogenesis, diagnosis and work-up
Date: 2024-10-05 Authors:Robert Bissonnette 1, Tove Agner2, Sonja Molin3, Emma Guttman-Yassky4 Category: Eczema Read more on pubmed
Hand Eczema. Part 2: Prevention, management, and treatment
Date: 2024-9-11 Authors:Robert Bissonnette 1, Tove Agner2, James S Taylor3, Sonja Molin4, Emma Guttman-Yassky5 Category: Eczema Read more on pubmed
Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity
Date: 2024-03-20 Authors: Jonathan I Silverberg 1, Tove Agner2, Keith Baranowski3, Ursula Plohberger3, Henrik Thoning3, Rob Arbuckle4, Laura Grant4, George Skingley4, Robert Bissonnette5 Category: Dermatitis Background: This study aimed to evaluate the psychometric properties of the IGA-CHE for use as an outcome measure in CHE clinical trials and clinical practice. Read more on pubmed
